By: Molly Chiu From: bcm.edu The combination of CDK4/6 inhibitors with endocrine therapy is the standard of care for patients with estrogen receptor-positive (ER+) and HER2-negative (ER+/HER2-) metastatic breast cancer. However, a subset of patients will have tumors with intrinsic resistance to this therapy and most patients will develop resistant disease at some point during treatment. Researchers at the Lester …
Triggering antiviral immune response in certain breast cancers
By: Molly Chiu From: bcm.edu Researchers at Baylor College of Medicine have discovered how therapeutics targeting RNA splicing can activate antiviral immune pathways in triple negative breast cancers (TNBC) to trigger tumor cell death and signal the body’s immune response. A new study published in Cell shows that endogenous mis-spliced RNA in tumor cells mimics an RNA virus, leading tumor …
Neurofibromatosis gene provides new insight into breast cancer resistance to hormone therapy
By: Baylor College of Medicine From: medicalxpress.com An international team of researchers led by scientists at Baylor College of Medicine has new insights into the function of neurofibromin, a tumor suppressor produced by the NF1 gene. It is well known that neurofibromin keeps cancer growth in check by repressing the activity of a cancer driver called Ras. The new research …
What Influence Do Treatment Costs Have on Breast Cancer Surgery Preferences?
By: Christina Bennett, MS From: cancernetwork.com When deciding about surgery for breast cancer, women, especially those with a lower household income, factored cost of treatment into their decision, according to a study reported in the Journal of Oncology Practice. Julie Nangia, MD, an assistant professor of medicine at the Lester and Sue Breast Center at Baylor College of Medicine, Houston, …
Diverse immune cell profiles and roles found in breast cancer resistance to immunotherapy
Source: Baylor College of Medicine From: sciencedaily.com Researchers show that heterogeneity of both breast cancer cells themselves and immune composition of the tumor microenvironment are important considerations for therapy. In recent years it has been increasingly appreciated that immune cells within the tumor microenvironment contribute to tumor progression and, importantly, to the tumor’s response to therapy. To better understand the …
Potential new strategy to fight ovarian cancer found
From: bcm.edu A new discovery opens the possibility of developing a novel way to fight ovarian cancer. Researchers at Baylor College of Medicine and the University of Texas MD Anderson Cancer Center have revealed a previously unknown cellular pathway that selectively regulates a mutant protein, called p53-R175H, linked to ovarian cancer growth. The researchers identified a key regulator of this …
New technique tests therapies for breast cancer metastasis
By: Allison Huseman From: bcm.edu A new laboratory technique developed by researchers at Baylor College of Medicine and other institutions can rapidly test the effectiveness of treatments for life-threatening breast cancer metastases in bone. The study appears in Nature Communications. “For a number of breast cancer patients, the problem is metastasis – the dissemination of breast tumor cells to other …